Loss of Anti-Tumor Efficacy by Polyamine Blocking Therapy in GCN2 Null Mice.

Loss of Anti-Tumor Efficacy by Polyamine Blocking Therapy in GCN2 Null Mice.
复制标题

DOI:
10.3390/biomedicines11102703
复制
发表时间:
2023-10-05
期刊:
影响因子:
4.7
通讯作者:
--
中科院分区:
工程技术3区
文献类型:
--
作者:

文献摘要

参考文献

相似文献

GCN 2是氨基酸饥饿应激的主要传感器之一,其在应激肿瘤微环境中的激活对肿瘤的生存和进展起着至关重要的作用。我们假设多胺生物合成的升高和随后前体精氨酸的耗尽激活GCN 2,从而重新连接代谢以支持肿瘤细胞存活并驱动骨髓免疫抑制功能。我们试图确定多胺阻断疗法(PBT)的抗肿瘤功效是否可能通过其对GCN 2的作用介导。与野生型小鼠不同,在携带同基因B16.F10或EG7肿瘤的GCN 2敲除小鼠中进行PBT治疗不会导致肿瘤生长抑制,也不会改变浸润肿瘤免疫细胞的分布。对小鼠骨髓细胞培养物的研究表明,多胺代谢增加和随后的精氨酸消耗和GCN 2活化在髓源性抑制细胞(MDSC)的产生和细胞保护性自噬以及巨噬细胞的M2极化和存活中起着至关重要的作用,所有这些都被PBT抑制。总之,我们的数据表明,基质细胞中的多胺依赖性GCN 2信号传导促进肿瘤生长和免疫抑制性肿瘤微环境的发展,并且PBT抗肿瘤作用至少部分地通过靶向GCN 2介导。
GCN2 is one of the main sensors of amino acid starvation stress, and its activation in the stressful tumor microenvironment plays a crucial role in tumor survival and progression. We hypothesized that elevated polyamine biosynthesis and subsequent depletion of precursor arginine activates GCN2, thus rewiring metabolism to support tumor cell survival and drive myeloid immunosuppressive function. We sought to determine if the anti-tumor efficacy of a polyamine blocking therapy (PBT) may be mediated by its effect on GCN2. Unlike wild-type mice, PBT treatment in GCN2 knockout mice bearing syngeneic B16.F10 or EG7 tumors resulted in no tumor growth inhibition and no changes in the profile of infiltrating tumor immune cells. Studies with murine bone marrow cell cultures showed that increased polyamine metabolism and subsequent arginine depletion and GCN2 activation played an essential role in the generation and cytoprotective autophagy of myeloid derived suppressor cells (MDSCs) as well as the M2 polarization and survival of macrophages, all of which were inhibited by PBT. In all, our data suggest that polyamine-dependent GCN2 signaling in stromal cells promotes tumor growth and the development of the immunosuppressive tumor microenvironment, and that the PBT anti-tumor effect is mediated, at least in part, by targeting GCN2.
DOI: 10.18632/oncotarget.20493
发表时间: 2017-10-13
期刊: Oncotarget
影响因子: --
作者:
Alexander ET;Minton A;Peters MC;Phanstiel O 4th;Gilmour SK
通讯作者: Gilmour SK
DOI: 10.1016/s0006-291x(88)80042-1
发表时间: 1988-11-30
影响因子: 3.1
作者:
CHANG, BK;LIBBY, PR;PORTER, CW
通讯作者: PORTER, CW
DOI: 10.1126/sciimmunol.aax8189
发表时间: 2019-12-01
期刊: SCIENCE IMMUNOLOGY
影响因子: 24.8
作者:
Halaby, Marie Jo;Hezaveh, Kebria;McGaha, Tracy L.
通讯作者: McGaha, Tracy L.
DOI: 10.3390/ijms18092016
发表时间: 2017-09-20
影响因子: 5.6
作者:
Ngabire D;Kim GD
通讯作者: Kim GD
多胺代谢和癌症:治疗,挑战和机遇。
DOI: 10.1038/s41568-018-0050-3
发表时间: 2018-11
期刊: Nature reviews. Cancer
影响因子: --
作者:
Casero RA Jr;Murray Stewart T;Pegg AE
通讯作者: Pegg AE